Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Durvalumab in Resected Esophageal Squamous Cell Carcinoma
NCT02520453Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Feb 2016
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02520453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520453.